Form 4: OrbiMed Advisors Sells Shares of ARS Pharmaceuticals (SPRY)

OrbiMed Advisors LLC, along with related entities, sold shares of ARS Pharmaceuticals (SPRY) between August 21 and August 23, 2024.

Summary

• OrbiMed Advisors LLC, OrbiMed Capital GP VI LLC, and OrbiMed Capital LLC filed a Form 4 detailing changes in beneficial ownership of ARS Pharmaceuticals, Inc. (SPRY).
• The transactions involved the sale of common stock by OrbiMed entities between August 21, 2024, and August 23, 2024.
• On August 21, 2024, 394,400 shares were sold at a weighted average price of $13.52, and 13,300 shares were sold at a weighted average price of $14.61.
• On August 22, 2024, 391,482 shares were sold at a weighted average price of $12.94.
• On August 23, 2024, 69,500 shares were sold at a weighted average price of $13.03.
• Following these transactions, OrbiMed entities still indirectly hold a significant number of shares through various investment funds and holding companies.

Sentiment

Score: 5

Explanation: Neutral sentiment as it's a standard disclosure of share sales; no explicit positive or negative outlook is provided.

Negatives

• OrbiMed Advisors reduced its direct holdings in ARS Pharmaceuticals through a series of sales.

Industry Context

Form 4 filings are routine disclosures for significant shareholders and provide transparency into their trading activities. Large institutional investors like OrbiMed often adjust their holdings as part of portfolio management strategies.

Stakeholder Impact

• Shareholders may react to the news of OrbiMed's share sales, potentially impacting the stock price.

Key Dates